Remove Funds Remove Medical Remove Public Trading
article thumbnail

Cooley’s 2019 Life Sciences M&A Year in Review

Cooley M&A

A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019, with aggregate deal value in the pharmaceutical, medical and biotech industry reaching $234.2 Year of the Life Sciences Mega-Deals. billion acquisition of The Medicines Company.

M&A 40
article thumbnail

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cooley’s 2021 Life Sciences M&A Year in Review

Cooley M&A

A notable example was a consortium of PE funds agreeing to acquire a majority stake in Medline for $34 billion. For example, early in 2021, Zimmer Biomet Holdings announced that it would spin off its spine and dental businesses into a new publicly traded company as a way to “optimize resource allocation” among its remaining businesses.

M&A 40
article thumbnail

Cooley’s 2022 Tech M&A Year in Review

Cooley M&A

Going further, rather than arranging upfront committed debt financing, Thoma Bravo opted to fund the purchase price for its announced $2.3 Looking forward, we should expect even more enforcement as the agencies continue to execute the Biden administration’s mandate for increased enforcement and receive additional funding for that mission.

M&A 52
article thumbnail

Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?

Cooley M&A

Public company deals: Smaller bites in more focused therapeutic areas The landscape for public company sales in the life sciences sector in 2024 was notably quieter than expected, with anticipated high-profile deals failing to materialize. Similarly, Novo Holdings $16.5

M&A 64